Course of renal involvement in the short term in children with coronavirus disease 2019

Sandra M. Martin, M.D.,* Luciana Meni Battaglia, M.D.,* M. Laura Beaudoin, M.D.,† M. Cecilia Torres Pérez, M.D.,‡ and Alejandro Balestracci, M.D.*

ABSTRACT
Renal involvement among pediatric patients with coronavirus disease 2019 (COVID-19) ranges between 10% and 80%. Given the limited information about its prognosis, the objective of this study was to describe the short-term course of patients in whom renal involvement was detected during hospitalization due to COVID-19.

This was an observational, cross-sectional study in patients aged 1 month to 18 years who had COVID-19 and renal involvement. Those with a known kidney disease were excluded. A total of 27 patients with renal involvement were identified; 14 of them were followed-up to study their disease course for 3 months after diagnosis. All of the patients had achieved normal plasma creatinine levels during hospitalization and, at the time of outpatient follow-up, which took place 145 days (92-193) later, all had normal blood pressure and urinary values, except for 1 patient who continued with microscopic hematuria. Course was favorable; in most patients, renal involvement had fully resolved.

Key words: COVID-19, acute kidney injury, child, prognosis.

http://dx.doi.org/10.5546/aap.2021.eng.414

INTRODUCTION
In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was recognized as the causative factor of coronavirus disease 2019 (COVID-19), which has led to a pandemic. SARS-CoV-2 infection has a high prevalence of pneumonia, but it also affects other organs.¹ In children, it usually has a favorable course compared to adults, and half remain asymptomatic.¹ However, it may occur with multisystem involvement, including hyperinflammatory shock.¹

The prevalence of renal involvement in children with COVID-19 ranges between 10% and 80%, depending on the severity of their clinical condition.² To the authors’ knowledge, there are still no studies describing the course of these patients. Therefore, the objective of this study was to describe the course of renal involvement in the short term among patients hospitalized due to COVID-19.

PATIENTS AND METHODS
This was an observational, cross-sectional study that included patients hospitalized at Hospital de Niños Pedro de Elizalde between May and October 2020 who: a) had confirmed SARS-CoV-2 infection and renal involvement, identified through a previous multicenter study aimed at assessing the prevalence of renal involvement in COVID-19, which required a minimum creatinine level and/or a urine test for inclusion; and b) were between 1 month and 18 years old. Identified patients were scheduled to study their renal course 3 months after diagnosis. Those with a known kidney disease were excluded.

The study was approved by the hospital’s Ethics Committee, and a written informed consent and/or assent was obtained as applicable (protocol no. 3597-2021).

Renal involvement was defined as the presence of acute kidney injury (AKI), pathological proteinuria, hematuria, leukocyturia and/or arterial hypertension (HTN). During hospitalization, the following data were recorded: age, sex, previous diseases, clinical severity upon admission, admission to the intensive care...
Definitions

SARS-CoV-2 infection: detected by polymerase chain reaction performed on nasopharyngeal aspirates or positive serology (IgM and/or IgG).³

Renal involvement was assessed based on the presence or absence of:

- AKI: creatinine (mg/dL) > 1.5 times the upper value of normal for age.³⁵
- Hematuria: > 5 red blood cells per high-powered field.⁶
- Pathological proteinuria: presence of 1 or more crosses in the urine strip or urine protein/creatinine ratio on spot urine sample >0.2.⁹
- Leukocyturia: presence of ≥ 5 white blood cells per high-powered field.⁹
- HTN: systolic and/or diastolic blood pressure ≥ 95th percentile and < 95th percentile + 12 mmHg for age, sex, and height in subjects younger than 16 years and systolic blood pressure between 140 and 159 mmHg and/or diastolic blood pressure between 90 and 99 mmHg in subjects older than 16 years (according to the guidelines of the National Program for School Health [Programa Nacional de Salud Escolar, PROSANE]).³

Clinical condition upon admission was defined as follows:

- Asymptomatic: diagnosed through close contact tracing, no symptoms.
- Mild: patients without risk factors, no oxygen therapy requirement or parenteral hydration with normal vital signs and non-specific symptoms.
- Moderate: patients with respiratory distress, who require oxygen therapy and/or parenteral hydration or have mild conditions in a risk group.
- Severe: patients with severe respiratory distress with clinical symptoms compatible with compensated septic shock.
- Critical: patients with impending acute respiratory failure, decompensated shock or cardiorespiratory arrest.⁰

Multisystem inflammatory syndrome in children (MIS-C): children with fever for more than 3 days and 2 of the following: a) skin rash or bilateral conjunctivitis or signs of mucocutaneous inflammation; b) hypotension or shock; c) myocardial dysfunction, pericarditis, valvulitis or coronary artery anomalies; d) coagulopathy; and e) acute gastrointestinal symptoms, with elevated markers of inflammation.¹¹,¹²

Statistical analysis

A descriptive analysis was done; continuous variables were expressed as median (range) because data did not have a normal distribution (Shapiro-Wilk test) and categorical variables were described as frequency of occurrence and/or percentage. The Statistix 7th software (IBM version, FL) was used.

RESULTS

In the study period, 435 patients with COVID-19 were hospitalized. After reviewing the medical records for the mentioned study, 346 cases were included (255 had mild and/or asymptomatic forms); of these, 27 (7.8%) had renal involvement (Figure 1). Among the latter, 7 had previous diseases. The most frequent manifestation of renal involvement was proteinuria, observed in 17 cases, followed by microscopic hematuria in 8, leukocyturia in 7, and AKI in 2; no patient required RRT or developed HTN. All had achieved normal plasma levels during hospitalization, but they had no urine tests done before hospital discharge to determine whether the renal condition had completely resolved. To study their course, patients were contacted for an outpatient follow-up. Thirteen of them were not assessed: 11 were not located, 1 developed Henoch-Schönlein purpura at 3 months, and the other patient died 2 months later due to sepsis, with histiocytosis as an underlying condition (Figure 1). Therefore, renal course was assessed in 14 patients (8 males; median age: 5.2 years; range: 0.5-16.1). In this subgroup, the distribution of renal involvement was as follows: proteinuria in 10 cases, leukocyturia in 6, microscopic hematuria in 3, and AKI in 1. Three patients had previous diseases and 4 of them developed severe forms (Table 1). The latter required admission to the ICU for 2.5 days (1-7) due to MIS-C, 1 required mechanical ventilation, 2 received inotropic agents, 1 developed AKI, and all had significant proteinuria. When patients were assessed in the outpatient follow-up, 140 days (92-193) had elapsed since the onset of COVID-19. All continued having normal blood pressure and urinary findings returned to normal, except for 1 patient who still had microscopic hematuria (Table 1).
DISCUSSION
The etiopathogenesis of renal involvement caused by COVID-19 is little-known and implies glomerular and tubular damage due to viral invasion in addition to an imbalance in the inflammatory and renin-angiotensin-aldosterone systems.\textsuperscript{13,14}

Pediatric patients with COVID-19 have a more favorable course than adults, with a mortality rate of less than 1%.\textsuperscript{1} By indication of the National Ministry of Health of Argentina, when the pandemic started, all patients were hospitalized, even if asymptomatic. The rate of renal involvement of hospitalized patients included in the previous multicenter study (not published) was 7.8%. Among hospitalized adults, the rate of renal involvement is approximately 30%,\textsuperscript{14} whereas in pediatrics it is variable. Stewart et al.\textsuperscript{3} observed in 52 children a prevalence of 77%. On the contrary, and consistent with other pediatric series,\textsuperscript{1,2} in the patients included in this study, renal involvement was less frequent, probably because most had mild forms.

In relation to the type of renal involvement, among adults, significant proteinuria was observed in 40-60%; hematuria, in 20-40%; leukocyturia in 30%; and AKI, in 15%, with RRT requirement in 5% of cases.\textsuperscript{13,14} In addition, in pediatric patients, high creatinine levels were observed in 46%; significant proteinuria, in 42%; and microscopic hematuria, in 77%.\textsuperscript{3} In the patients included in this study, findings were mostly mild and non-specific and may have been caused by factors extrinsic to COVID-19. In them, as in adults, significant proteinuria prevailed.\textsuperscript{12,14}

The course of renal involvement in pediatric patients with COVID-19 is uncertain. In this series, it was excellent, regardless of the severity of the disease. Actually, out of the 4 patients who had renal involvement and required admission to the ICU, all developed MIS-C and only 1 developed AKI but did not require RRT and achieved a normal renal function before hospital discharge. Stewart et al.\textsuperscript{3} observed that 38% of patients admitted to the ICU developed AKI (46% with MIS-C) but did not require dialysis.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Flow chart of included patients}
\end{figure}

135 patients with COVID-19

89 were not included: 78 had no laboratory data
7 were out of the age range
4 had a previous kidney disease

346 were admitted to the previous protocol

27 had renal involvement:
10 proteinuria
5 proteinuria/leukocyturia
6 microscopic hematuria
2 microscopic hematuria/proteinuria
2 leukocyturia
2 acute kidney injury

13 were excluded: 11 were not located
1 died
1 debuted with Henoch-Schönlein purpura

14 were analyzed:
4 proteinuria
5 proteinuria/leukocyturia
2 microscopic hematuria
1 microscopic hematuria/proteinuria
1 leukocyturia
1 acute kidney injury

13 showed resolution
1 microscopic hematuria
<table>
<thead>
<tr>
<th>Patient</th>
<th>Renal involvement</th>
<th>Age</th>
<th>Sex</th>
<th>Previous disease</th>
<th>Upon admission</th>
<th>Stay in ICU (days)</th>
<th>MIS-C (ng/dL)</th>
<th>Creatinine (mg/dL)</th>
<th>Prot/Cr</th>
<th>Hematuria</th>
<th>Leukocyturia</th>
<th>Urine culture</th>
<th>Days after diagnosis</th>
<th>Prot/Cr</th>
<th>Hematuria</th>
<th>Leukocyturia</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>P, L</td>
<td>5.25</td>
<td>F</td>
<td>No</td>
<td>Moderate</td>
<td>0</td>
<td>No</td>
<td>0.3</td>
<td>0.26</td>
<td>No</td>
<td>Yes</td>
<td>NP</td>
<td>148</td>
<td>0.15</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>P, L</td>
<td>4.25</td>
<td>M</td>
<td>No</td>
<td>Severe</td>
<td>7</td>
<td>Yes</td>
<td>0.46</td>
<td>0.69</td>
<td>No</td>
<td>No</td>
<td>NP</td>
<td>193</td>
<td>0.14</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>P</td>
<td>2.83</td>
<td>F</td>
<td>ROB</td>
<td>Asymptomatic</td>
<td>0</td>
<td>No</td>
<td>0.22</td>
<td>No</td>
<td>No</td>
<td>NP</td>
<td>148</td>
<td>0.17</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>P, L</td>
<td>12.06</td>
<td>F</td>
<td>No</td>
<td>Moderate</td>
<td>0</td>
<td>No</td>
<td>0.53</td>
<td>0.27</td>
<td>No</td>
<td>Yes</td>
<td>Streptococcus oralis (contaminant)</td>
<td>118</td>
<td>0.07</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>P, L</td>
<td>4.58</td>
<td>F</td>
<td>No</td>
<td>Mild</td>
<td>0</td>
<td>No</td>
<td>0.68</td>
<td>0.3</td>
<td>No</td>
<td>Yes</td>
<td>Escherichia coli; 10^3 CFU/mL</td>
<td>128</td>
<td>0.15</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>P</td>
<td>2.50</td>
<td>M</td>
<td>ROB</td>
<td>Mild</td>
<td>0</td>
<td>No</td>
<td>0.46</td>
<td>0.27</td>
<td>No</td>
<td>No</td>
<td>NP</td>
<td>168</td>
<td>0.16</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>7</td>
<td>AKI, P, L</td>
<td>5.16</td>
<td>M</td>
<td>No</td>
<td>Severe</td>
<td>4</td>
<td>Yes</td>
<td>3.08</td>
<td>++</td>
<td>No</td>
<td>Yes</td>
<td>Negative</td>
<td>142</td>
<td>Negative</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>8</td>
<td>H</td>
<td>11.91</td>
<td>M</td>
<td>Mild</td>
<td>0</td>
<td>No</td>
<td>0.47</td>
<td>Negative</td>
<td>No</td>
<td>No</td>
<td>NP</td>
<td>113</td>
<td>0.15</td>
<td>&gt;15</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>9</td>
<td>P, L</td>
<td>6.66</td>
<td>F</td>
<td>No</td>
<td>Asymptomatic</td>
<td>0</td>
<td>No</td>
<td>0.46</td>
<td>0.22</td>
<td>No</td>
<td>Yes</td>
<td>NP</td>
<td>163</td>
<td>0.11</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>10</td>
<td>P</td>
<td>2.5</td>
<td>M</td>
<td>West syndrome</td>
<td>Mild</td>
<td>0</td>
<td>No</td>
<td>0.26</td>
<td>0.3</td>
<td>No</td>
<td>No</td>
<td>NP</td>
<td>159</td>
<td>0.19</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>11</td>
<td>P, L</td>
<td>8.58</td>
<td>M</td>
<td>No</td>
<td>Severe</td>
<td>1</td>
<td>Yes</td>
<td>0.59</td>
<td>+</td>
<td>No</td>
<td>Yes</td>
<td>NP</td>
<td>163</td>
<td>0.09</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>12</td>
<td>L</td>
<td>0.75</td>
<td>F</td>
<td>No</td>
<td>Mild</td>
<td>0</td>
<td>No</td>
<td>0.18</td>
<td>Negative</td>
<td>No</td>
<td>Yes</td>
<td>Negative</td>
<td>101</td>
<td>0.23</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>13</td>
<td>H, L</td>
<td>6.41</td>
<td>M</td>
<td>No</td>
<td>Mild</td>
<td>0</td>
<td>No</td>
<td>0.42</td>
<td>+</td>
<td>Yes</td>
<td>No</td>
<td>NP</td>
<td>123</td>
<td>0.18</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>14</td>
<td>H, P</td>
<td>11.91</td>
<td>M</td>
<td>No</td>
<td>Severe</td>
<td>1</td>
<td>Yes</td>
<td>0.55</td>
<td>+</td>
<td>Yes</td>
<td>Negative</td>
<td>92</td>
<td>0.1</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

In patients with severe forms included in this study, like in the others, urinary findings resolved after 3 months, except in 1 who continued with microscopic hematuria. The presence of previous diseases did not worsen renal involvement either. The limitations of this study were the small sample size, the high percentage of patients who were lost-to-follow-up, the scarce number of patients with severe forms studied, and the relatively short follow-up duration, since it is known that patients with AKI should receive follow-up in the long term. However, although findings should not be generalized, given the fact that this is a new disease, the information presented here may be clinically useful.

CONCLUSION
In most patients included in this study, renal involvement resolved completely in the short term. Further studies are required to corroborate these data.

REFERENCES


